Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial.

Landewé RB, Houbiers JG, Van den Bosch F, in't Hout J, Verschueren PC, Meijerink JH, van den Hoogen FH, Masek BA, Bruyn GA, Wouters JM, Voskuyl AE, van Laar JM, Bijlsma JJ, van der Heijde DM, Breedveld FC, van de Putte LB, Miltenburg AM, de Keyser F.

Ann Rheum Dis. 2010 Sep;69(9):1655-9. doi: 10.1136/ard.2009.117234. Epub 2009 Sep 23.

PMID:
19778914
2.

Intranasal administration of recombinant human cartilage glycoprotein-39. A phase I escalating cohort study in patients with rheumatoid arthritis.

Zandbelt MM, Houbiers JG, van den Hoogen FH, Meijerink J, van Riel PL, in't Hout J, van de Putte LB.

J Rheumatol. 2006 Sep;33(9):1726-33.

PMID:
16960935

Supplemental Content

Loading ...
Support Center